MADRID -- The novel oral cardiac myosin inhibitor aficamten improved exercise capacity and symptoms of obstructive hypertrophic cardiomyopathy (HCM) better than standard beta-blocker treatment, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback